|Mr. Andrew G. Long||CEO & Director||697.1k||N/A||1965|
|Mr. Mark E. Nance||Chief Legal Officer & Gen. Counsel||360.16k||N/A||1968|
|Ms. Andrece Housley||Chief Financial Officer||N/A||N/A||1968|
|Dr. Danny L. Tuck||Sr. VP of Quality Operations||N/A||N/A||N/A|
|Dr. Venkat Reddy Goskonda Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona. On June 10, 2019, INSYS Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
INSYS Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 10. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 10; Compensation: 10.